Free Trial
NASDAQ:DRMA

Dermata Therapeutics (DRMA) Stock Price, News & Analysis

Dermata Therapeutics logo
$0.67 0.00 (-0.15%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$0.67 0.00 (0.00%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dermata Therapeutics Stock (NASDAQ:DRMA)

Key Stats

Today's Range
$0.65
$0.70
50-Day Range
$0.59
$0.91
52-Week Range
$0.57
$5.00
Volume
42,072 shs
Average Volume
1.18 million shs
Market Capitalization
$4.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Buy

Company Overview

Dermata Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

DRMA MarketRank™: 

Dermata Therapeutics scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dermata Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Dermata Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dermata Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dermata Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dermata Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dermata Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.36% of the float of Dermata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dermata Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Dermata Therapeutics has recently increased by 8.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Dermata Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dermata Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.36% of the float of Dermata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dermata Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Dermata Therapeutics has recently increased by 8.27%, indicating that investor sentiment is decreasing significantly.
  • MarketBeat Follows

    Only 1 people have added Dermata Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.50% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 8.67% of the stock of Dermata Therapeutics is held by institutions.

  • Read more about Dermata Therapeutics' insider trading history.
Receive DRMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DRMA Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

DRMA Stock Analysis - Frequently Asked Questions

Dermata Therapeutics' stock was trading at $1.35 at the beginning of the year. Since then, DRMA shares have decreased by 50.7% and is now trading at $0.6660.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45).

Dermata Therapeutics shares reverse split on the morning of Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Dermata Therapeutics (DRMA) raised $18 million in an initial public offering (IPO) on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN).

Company Calendar

Last Earnings
5/14/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DRMA
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+350.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.29 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.62 per share
Price / Book
1.07

Miscellaneous

Free Float
5,198,000
Market Cap
$4.25 million
Optionable
Not Optionable
Beta
0.54
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:DRMA) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners